|Earth Science Secures Second Provisional Patent for Its CBD Rich Hemp Oil; Neurocrine Announces Granting of Orphan Drug Status for NBI-77860|
|By William Kent|
|Friday, 16 January 2015 19:54|
Earth Science Tech, Inc. (OTCQB: ETST), a unique biotechnology company focused on nutraceuticals, bioceuticals and dietary supplements, announced it has secured, and been assigned, a second ground breaking new provisional patent named "Cannabidiol Compositions and Uses 2," Serial No. 62102538, with the United States Patent and Trademark Office (USPTO) for Hemp Oil Enriched with CBD (Cannabidiol) and Hemp Oil Enriched with Proprietary Additives. This new patent was filed on January 12, 2014 by the inventors: Dr. Harvey Katz, the CEO of Earth Science Tech, Dr. Wei R. Chen, the assistant dean of the College of Mathematics and Science at the University of Central Oklahoma (UCO), and Dr. Feifan Zhou. On January 14, 2014 the inventors Dr. Harvey Katz, Dr. Wei Chen and Dr. Feifan Zhou assigned the Provisional Patent "Cannabidiol Compositions and Uses 2," Serial No. 62102538, to Earth Science Tech, Inc. (ETST). The assignors have hereby transferred to the assignee (ETST), its successors and assigns, the entire right, title and interest in, and to the invention throughout the world, the above identified application, all corresponding domestic and foreign applications, all Letters Patent or similar legal protection issuing thereon, and all rights and benefits under any applicable treaty or convention.
Partial Abstract of new Patent Serial No. 62102538: A composition having cannabidiol, alone, or as a component of hemp oil, for use in treating or preventing cancer. The composition may include D-limonene, which contributes synergistically to the anticancer efficacy of the composition. With this second (2nd) new provisional patent ETST has a total of ten (10) new claims.Under the sponsorship of ETST, researchers at the University of Central Oklahoma have been investigating the effects of CBD on immune cells with ETST using the ETST CBD Rich Hemp Oil. This new patent has been filed because of ETST new findings under its sponsorship with the University of Central Oklahoma. These finding are breakthroughs in this field and are a result of the ETST new relationship with its international raw supplier of a higher quality CBD Rich Hemp Oil. ETST plans on releasing the results in the next several days and feels it will have a great impact on the entire CBD Rich Hemp Oil marketplace.
In order to protect the valuation of this patent and its intellectual properties, ETST cannot completely reveal the full nature of this patent at this time or site any of the claims or studies until the patent or patents are issued by the PTO. There will be a number of new claims on the provisional patent before the final Utility Patent is filed. This will be within the one year time limit for the Utility Patent to be filed. ETST has formed solid partnerships and relationships with a wide variety of international players in the nutritional and dietary supplement markets as well as in the Hemp Industry. ETST is quickly becoming a leader in the CBD Rich Hemp Oil marketplace. ETST is in the business of manufacturing and marketing products which utilize the CBD component of hemp oil for nutritional and palliative purposes.
CEO of ETST, Dr. Harvey Katz stated, "I am very delighted to see that our efforts and positive developments with Dr. Wei Chen along with Dr. Feifan Zhou and the University of Central Oklahoma have resulted in the second (2nd) filing of a patent application with the United States Patent and Trademark Office (USPTO) for Hemp Oil Enriched with CBD (Cannabidiol). The filing of this second (2nd) patent application and assignment to ETST is just the beginning of many other great things to come. As previously stated ETST looks to build a strong intellectual property portfolio and it is doing just that. ETST now has 2 provisional patents and inventions with its CBD Rich Hemp Oil (patent Serial No. 62102538 and patent Serial No. 62061577). We look forward to continuing to grow ETST in order to help consumers Worldwide with their overall Health and Wellness through cutting edge Nutraceuticals and Dietary supplements."
As previously announced on October 20th, 2014, ETST Secured its first (1st) patent filing of its Hemp Oil Enriched with CBD (Cannabidiol) and Hemp Oil Enriched with Proprietary Additives (provisional patent filing Serial No. 62061577 "Cannabidols Composition and Uses Thereof") by its CEO Dr. Harvey Katz and esteemed University of Central Oklahoma Biomedical Engineering Program professor, and lead investigator for the ETST Sponsored Research Agreement, Dr. Wei Chen, a veteran laser cancer treatment specialist who received his master's and Ph.D. degrees in theoretical high-energy physics from the University of Oregon. Dr. Wei R. Chen has done extensive work in the area of laser treatment of breast cancer and is working with a foreign drug company to advance and exploit the technology under development. Dr. Chen is a world renowned scientist, researcher and university professor whose laboratory is prominent in various areas including the application of CBD (Cannabidiol).
Once again the company would like to state, "We are very delighted with the advances and developments of Dr. Wei Chen and the College of Mathematics and Science at the University of Central Oklahoma working with us on our CBD Rich Hemp Oil. ETST is focused on making a positive and significant impact in the health and wellness industry through new cutting edge formulations with its CBD Rich Hemp Oil for the Nutritional and Dietary Supplement markets."
Neurocrine Biosciences (NASDAQ: NBIX) announced NBI-77860, a proprietary corticotropin releasing factor 1 (CRF) receptor antagonist, has been granted orphan drug status by the United States Food and Drug Administration (FDA) for the treatment of congenital adrenal hyperplasia (CAH) a disease that affects approximately 20,000-30,000 people in the United States.
"We are very pleased that the FDA has granted NBI-77860 orphan status to treat congenital adrenal hyperplasia, a devastating disease that is a significant challenge for both clinicians and patients," said Malcolm Lloyd-Smith, Chief Regulatory Officer of Neurocrine Biosciences. "This status represents a significant regulatory milestone for the CAH program and underscores the importance of bringing a safe and effective CAH therapy to market. We look forward to the results from our recently initiated 1401 Study of adolescents with classic CAH, in 2015."
BioMed Realty Trust (NYSE: BMR) today announced the tax treatment of its 2014 distributions.
Emergency Medical Associates (EMA) announced that it has been acquired by the EmCare, Inc., subsidiary of Envision Healthcare Holdings, Inc. (NYSE: EVHC) (Envision).
Express Scripts (NASDAQ: ESRX) announced today its intention to release its fourth quarter and full year earnings and 2015 earnings guidance on Monday, February 23, 2015 after the market closes and will hold its quarterly conference call to discuss fourth quarter and full year results and 2015 earnings guidance on Tuesday, February 24, 2015, at 8:30 a.m. Eastern Time (7:30 a.m. Central Time).
FluoroPharma Medical, Inc. (OTCQB: FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, today announced that its VP Marketing, Ed Lyons, will present at the Noble Financial Capital Markets' Eleventh Annual Equity Conference at Club Med in Sandpiper Bay, Florida, on Wednesday January 21st at 9:30am Eastern Standard Time.
Herborium® Group, Inc.(OTC Pink: HBRM), a Botanical Therapeutics® Company providing unique, all botanical medicines (Botanical Therapeutics®), announced today that the Company's CEO, Dr. Agnes P. Olszewski will be interviewed live by Michael Yorba, the host, on Clear Channel - iHeart Business Talk Radio's "The Trader's Network" Show on January 17th, 2015.
Medovex Corp. (NASDAQ: MDVXU), a developer of medical technology products including the DenerveX device, announced it has issued today an additional 208,695 of the Company's units, pursuant to the exercise in full of the underwriters' over-allotment option granted by the Company in connection with its initial public offering completed in December.
Merit Medical Systems, Inc. (Nasdaq:MMSI), a leading manufacturer and marketer of proprietary disposable medical devices used in interventional and diagnostic procedures, particularly in cardiology, radiology and endoscopy, announced today that the Company will release its financial results for the fourth quarter and year ended December 31, 2014, after the close of the stock market on Tuesday, February 24, 2015.
Novus Acquisition & Development Corp. (OTC PINK: NDEV), a provider of health and wellness savings plans through its wholly-owned subsidiary Novus Medical Group Inc., today announced that Chief Executive Officer Frank Labrozzi has returned 90 million of his personal common shares of NDEV to the company treasury.
OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, presented final safety, efficacy and biomarker data from the company's Phase 1b "ALPINE" clinical trial of tarextumab (anti-Notch2/3, OMP-59R5) in 40 patients with frontline metastatic pancreatic cancer.